secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amylyx Pharmaceuticals, Inc. (AMLX)
CIK:        0001658551
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0001193125-23-173965
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amylyx receives CHMP negative opinion for AMX0035 ALS approval in EU; will seek re-examination
--------------------------------------------------------------------------------

- CHMP adopted negative opinion on conditional marketing authorisation for AMX0035 (ALBRIOZA) for ALS in EU.
- Company will request formal re-examination, a ~4-month process with new rapporteur and co-rapporteur.
- Topline results from global Phase 3 PHOENIX study expected mid-2024.
- ALS affects ~30,000 people in Europe; no new ALS innovations approved in EU in over 25 years.
- AMX0035 is approved in the U.S. and with conditions in Canada based on CENTAUR trial data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1658551/000119312523173965/0001193125-23-173965-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1658551/000119312523173965/d470144d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-173965

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer